Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling

Johanna Bendell, Susanna V. Ulahannan, Marianna Koczywas, Julie Brahmer, Anna Capasso, S. Gail Eckhardt, Michael S. Gordon, Caroline Mccoach, Misako Nagasaka, Kimmie Ng, Jose Pacheco, Jonathan W. Riess, Alexander I Spira, Conor Steuer; Richa Dua, Suman Chittivelu, Serena Masciari, Zhengping Wang, Xiaolin Wang, Sai-Hong I. Ou


AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; October 24-25, 2020; held virtually; Presentation ORAL-005


Return to Media Home